Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (262)

2024

  1. A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy

    Toxicology, Vol. 509

  2. Assessing ATR-FTIR spectroscopy for steatosis quantification in liver biopsies in a long-duration cross-sectional study

    Microchemical Journal, Vol. 198

  3. Cluster-Partial Least Squares (c-PLS) regression analysis: Application to miRNA and metabolomic data

    Analytica chimica acta, Vol. 1286, pp. 342052

  4. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways

    International Journal of Molecular Sciences, Vol. 25, Núm. 10

  5. Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

  6. Progress and challenges of mid-infrared spectroscopy for liver characterization focusing on steatosis, fibrosis and cancer

    Applied Spectroscopy Reviews, Vol. 59, Núm. 4, pp. 578-599

2023

  1. Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation

    The Analyst, Vol. 148, Núm. 17, pp. 3986-3991

  2. Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference

    Analyst, Vol. 148, Núm. 13, pp. 3097-3106

  3. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients

    Nutrients, Vol. 15, Núm. 14

  4. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved

    Archives of Toxicology, Vol. 97, Núm. 6, pp. 1723-1738

  5. The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics

    Frontiers in Pharmacology, Vol. 14

2022

  1. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat

    International journal of molecular sciences, Vol. 23, Núm. 16

  2. The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

    Metabolites, Vol. 12, Núm. 6

2021

  1. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes

    Archives of Toxicology, Vol. 95, Núm. 9, pp. 3049-3062

2020

  1. A novel MicroRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients

    Toxicological Sciences, Vol. 173, Núm. 2, pp. 229-243

  2. Comparing targeted vs. untargeted MS2 data-dependent acquisition for peak annotation in LC–MS metabolomics

    Metabolites, Vol. 10, Núm. 4

  3. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes

    Archives of Toxicology, Vol. 94, Núm. 2, pp. 589-607

  4. Improved in vivo efficacy of clinical-grade cryopreserved human hepatocytes in mice with acute liver failure

    Cytotherapy, Vol. 22, Núm. 2, pp. 114-121

  5. Toward Rapid Screening of Liver Grafts at the Operating Room Using Mid-infrared Spectroscopy

    Analytical Chemistry, Vol. 92, Núm. 21, pp. 14542-14549

2019

  1. Monitoring of system conditioning after blank injections in untargeted UPLC-MS metabolomic analysis

    Scientific Reports, Vol. 9, Núm. 1